Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Neuromodulation group | Active Comparator |
| |
| Pseudoneuromodulation group | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neuroelectrical modulation group | Device | Participants received transcranial electrical stimulation using the Spanish Neuroelectrics StarStim 32 device. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Expanded Disability Status Scale, EDSS score | 0-10 points, the higher the score, the more serious | At the 5-day point of treatment and 1 month following the end of treatment |
| Symbol Digit Modalities Test (SDMT) scale | 0-110 points, the higher the score, the better the cognitive function | At the 5-day point of treatment and 1 month following the end of treatment |
| Scoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog) | the higher the score, the better the cognitive function | At the 5-day point of treatment and 1 month following the end of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Mini-mental State Examination(MMSE) | 0-30,the higher the score, the better the cognitive function | At the 5-day point of treatment and 1 month following the end of treatment |
| Montreal-Cognitive Assessment(MoCA) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| huang huijin, Ph.D. | Contact | +8618510510804 | huanghuijinmail@sina.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xuanwu Hospital, Capital Medical University | Recruiting | Beijing | Beijing Municipality | 100053 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pseudo-neuromodulation group | Device | Pseudo-stimulation is performed using the same equipment and procedures as in the neuromodulation group. |
|
0-30,the higher the score, the better the cognitive function
| At the 5-day point of treatment and 1 month following the end of treatment |
| Stroop Color-Word Test score | the higher the score, the better the cognitive function | At the 5-day point of treatment and 1 month following the end of treatment |
| Hamilton Depression Scale,HAMD | The higher the score, the worse the depression. | At the 5-day point of treatment and 1 month following the end of treatment |
| Hamilton Anxiety Scale,HAMA | The higher the score, the worse the anxiety. | At the 5-day point of treatment and 1 month following the end of treatment |
| a subjective questionnaire,adverse effects | The intensity is scored from 0 to 4 | Following the first day of treatment,Following the second day of treatment,Following the third day of treatment,Following the fourth day of treatment,Following the fifth day of treatment |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D004673 | Encephalomyelitis, Acute Disseminated |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D056784 | Leukoencephalopathies |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided